Showing 3571-3580 of 5646 results for "".
- Surrozen Discontinues Liver Program; Shifts Focus to Ophthalmologyhttps://modernod.com/news/surrozen-discontinues-liver-program-shifts-focus-to-ophthalmology/2482716/Surrozen announced that the company will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ophthalmology programs, including development of new treatment options for retinopathies. The company will use a $175-million private placement
- Alcon Boosts Femtosecond Laser Portfolio with Acquisition of Lensarhttps://modernod.com/news/alcon-boosts-femtosecond-laser-technology-with-acquisition-of-lensar/2482713/Alcon and Lensar have entered into a definitive merger agreement through which Alcon intends to acquire Lensar for about $356 million. The acquisition includes ALLY Robotic Cataract Laser Treatment System, Lensar’s proprietary Streamline software technology, and Lensar
- Unity Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in DMEhttps://modernod.com/news/unity-biotechnology-announces-topline-results-from-the-aspire-phase-2b-study-in-dme/2482712/Unity Biotechnology announced topline results from the phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment. The study results include data from all patients through 24 weeks, and the majori
- Study: Glaucoma Monitoring Lags in Low-Income and Rural Areashttps://modernod.com/news/study-glaucoma-monitoring-lags-in-low-income-and-rural-areas/2482710/A new Northwestern University study suggests that race, income and where patients live play a major role in the level of care glaucoma patients receive. Researchers found that Black, Hispanic and Asian American patients, as well as those from rural and economically distressed communities, are sig
- Lighthouse Guild Appoints Thomas Panek as New President and CEOhttps://modernod.com/news/lighthouse-guild-appoints-thomas-panek-as-new-president-and-ceo/2482706/Lighthouse Guild announced this morning that Thomas Panek has been appointed as President and CEO, effective April 2025. He succeeds Dr. Calvin W. Roberts, who has served in this role for the past 5 years. Mr. Panek has significant leadership experience with a deep commitment to a
- Iluvien Earns FDA Approval for Expansion to Treat Chronic Posterior Uveitishttps://modernod.com/news/iluvien-earns-fda-approval-for-expansion-to-treat-chronic-posterior-uveitis/2482704/ANI Pharmaceuticals announced that they the FDA has approved an expanded label for Iluvien to include treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). “Iluvien's expanded label and the strengthening of our pa
- Study Finds Most Glaucoma Patients Unaware of Preservative-Free Treatment Optionshttps://modernod.com/news/60-of-glaucoma-patients-unaware-of-preservative-free-treatment-options-study-from-preservative-freedom-coalition/2482698/The Preservative Freedom Coalition announced the results of a new nationwide survey delving into the experience of glaucoma patients to identify opportunities for improved communication with their eye care providers. This comes as Monday kicked o
- First Patients Enrolled in 4DMT's Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMDhttps://modernod.com/news/first-patients-enrolled-in-4dmts-phase-3-clinical-trial-evaluating-4d-150-in-wet-amd/2482694/4D Molecular Therapeutics (4DMT) announced that the first patients have been enrolled across multiple sites in the 4FRONT-1 phase 3 clinical trial evaluating 4D-150 for the treatment of wet age-related macular degeneration (AMD). "This is a historic moment for 4DMT as we becom
- Luxa Biotechnology Presents Data from First-in-Human Retinal Pigment Epithelium Cell Therapy for Dry AMDhttps://modernod.com/news/luxa-biotechnology-presents-data-from-first-in-human-retinal-pigment-epithelium-cell-therapy-for-dry-amd/2482693/Luxa Biotechnology announced clinical data from its phase 1/2a clinical trial evaluating RPESC-RPE-4W, a proprietary retinal pigment epithelium (RPE) cell therapy for patients with dry age-related macular degeneration (AMD). The data were presented at the 77th Annual Wills Eye Conference in Phila
- BVI Medical Raises $1 Billion to Fuel Global Growthhttps://modernod.com/news/bvi-medical-raises-1-billion-to-fuel-global-growth/2482692/BVI Medical has completed a $1 billion strategic capital raise in partnership with asset management firm TPG. According to BVI, the investment, which fully refinances BVI’s existing debt and adds new equity from both TPG and new investors, aims to strengthen the company&